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Use of polybrominated diphenyl ethers
(PBDEs) as ﬂame retardants (FRs) in plastics,
including electronic enclosures and poly-
urethane used in upholstery cushioning and
carpet pads, has increased steadily in the past
30 years (Alaee et al. 2003; de Wit 2002;
Hardy 2002b). PBDEs used as additive FRs
are more likely to leach over time than reac-
tive FRs, which are chemically bonded to the
plastic polymer (Alaee and Wenning 2002;
Eriksson et al. 2001; Sjodin et al. 2001a).
PBDEs are similar to polychlorinated
biphenyls (PCBs) in structure, lipophilicity,
persistence, and ability to bioaccumulate
(Hardy 2002a; McDonald 2002). Since the
1970s, environmental concentrations of
PCBs and other persistent organic pollutants
(POPs) have fallen whereas levels of PBDEs
have increased exponentially (Alaee and
Wenning 2002; Eriksson et al. 2001;
Meironyte et al. 1999; Sjodin et al. 2001b).
Currently, human PBDE levels are of a mag-
nitude similar to PCB concentrations in some
regions (Hites 2004; Petreas et al. 2004).
Human levels of PBDEs are higher in North
America than in Europe and within a given
population, a small fraction (5–10%) of indi-
viduals have concentrations far exceeding
average levels (Betts 2003; Hites 2004;
Schecter et al. 2005; Sjodin et al. 2003;
Wilford et al. 2005). Although there have
been no studies investigating the health
effects associated with PBDEs in humans,
there are reports of human exposure levels
that may be on par with levels eliciting harm-
ful effects in laboratory animals (McDonald
2005). Animal studies have shown evidence
of the disruption of normal endocrine func-
tion and neurodevelopmental, hepatic, and
reproductive toxicity (Betts 2004, 2005;
Johnson-Restrepo et al. 2005). 
Currently, there is an incomplete under-
standing of how humans are exposed to
PBDEs. It is reasonable to posit that among
those with high concentrations, occupational
exposures may be involved in some cases
(Sjodin et al. 1999; Thuresson et al. 2005).
In the general population, several potential
routes of PBDE exposure have been identi-
ﬁed: a) direct contact with treated products;
b) dietary, as these lipophilic compounds are
stored in the fat of meats, fish, and dairy
products (Harrad et al. 2004; Schecter et al.
2004, 2006; Wilford et al. 2005); and
c) ingestion and to a lesser degree inhalation
of PBDE-containing house dust (Jones-Otazo
et al. 2005; Stapleton et al. 2005; Wilford
et al. 2005; Wu et al. 2007) Only a few stud-
ies have been able to explore individual deter-
minants of PBDE body burdens in much
detail (Morland et al. 2005; Wu et al. 2007). 
Levels of PBDEs (as well as PCBs and
organochlorine pesticides) measured in adi-
pose tissue, blood, or milk can be used to
assess exposures (Sjodin et al. 2003). Infants
and fetuses are sensitive subpopulations to
consider, because these stages of development
may be especially susceptible to effects of
chemical exposures (Howdeshell 2002).
Toxicologic models have indicated that
immature animals have slower metabolism
and excretion of PBDEs; approximately 50%
of the administered 2,2´,4,4´-tetraBDE
(BDE-47) dose is excreted in the ﬁrst 24 hr in
adult animals compared with 31% and 41%
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BACKGROUND: Recent studies have reported blood levels of polybrominated diphenyl ethers
(PBDEs) in the U.S. population. Information about neonatal levels and about the relationship to
polychlorinated biphenyls (PCBs) exposures is limited. 
OBJECTIVES: The objective was to characterize levels and determinants of fetal exposure to PBDEs
and PCBs among newborns from Baltimore, Maryland. 
METHODS: We analyzed umbilical cord blood for eight PBDEs and 35 PCBs from infants delivered
at the Johns Hopkins Hospital. Maternal and infant characteristics were abstracted from medical
records. 
RESULTS: Ninety-four percent of cord serum samples had quantiﬁable levels of at least one PBDE
congener, and > 99% had at least one detectable PCB congener. PBDE concentrations in cord
blood were similar to those reported in other studies from North America. Strong correlations were
observed within but not across PCB and PBDE classes. Multivariate models showed that many fac-
tors independently predicted exposure to BDE-47, BDE-100, and BDE-153 and CB-118,
CB-138/158, CB-153, and CB-180. Generally, infants of Asian mothers had lower PBDE and
PCB levels, and infants of smokers had higher levels. Increased maternal body mass index was asso-
ciated with lower levels of PCBs but not PBDEs. Levels of PCBs but not PBDEs were lower in
births from married and multiparous mothers. Increased maternal age was associated with higher
PCB levels but lower PBDE levels. 
CONCLUSIONS: Although many of the factors we investigated were independent predictors of both
PBDE and PCB levels, in some cases the direction of associations was different. More research is
needed to better understand the sources and pathways of PBDE exposure. 
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(Staskal et al. 2006). Measuring PBDEs in
cord blood serum is noninvasive, using a
blood sample that is otherwise usually dis-
carded, and is a direct measure of prenatal
exposure. The estimated half-lives of these
compounds in humans are long enough—
BDE-47 1.8–3.0 years, 2,2´,4,4´,5-pentaBDE
(BDE-99) 2.9–5.4 years, and 2,2´,4,4´,5,5´-
hexaBDE (BDE-153) 6.5–11.7 years (Geyer
et al. 2004)—that cord blood concentrations
reflect exposure through the course of preg-
nancy. Such levels also provide a reasonable
estimate of maternal serum concentrations
(Mazdai et al. 2003). 
The principal objective of this investiga-
tion was to characterize fetal exposure to
PBDEs and selected PCBs among newborns
from Baltimore, Maryland, via the assessment
of concentrations in umbilical cord serum.
We explored demographic characteristics and
attributes to identify determinants and to
explain variations in exposure levels and pat-
terns within this largely urban and African-
American population. 
Materials and Methods
Study design and population. We conducted
a cross-sectional study of newborn deliveries
at the Johns Hopkins Hospital in Baltimore,
Maryland. In this study we examine the asso-
ciations between exposures to a number of
toxic chemicals, thyroid hormone levels, and
birth outcomes; determinants of PCB and
PBDE exposure are presented here. We col-
lected umbilical cord blood from a sample of
women presenting at the Johns Hopkins
Hospital for delivery of singleton births from
26 November 2004 to 16 March 2005.
Samples were excluded if the family wished to
archive cord blood or if samples yielded
< 5.2 mL of serum. During the study period,
of 597 singleton births delivered, 341 cord
blood samples were collected, of which 300
had sufficient serum volume for laboratory
analyses. A brief survey of hospital personnel
revealed that specimens were missed mainly
because of complications during delivery, pre-
mature birth and/or small size of the infant
resulting in small cord blood volume, and
logistical factors such as understaffing. This
study had the approval of the Maternal and
Fetal Research Committee in the Department
of Gynecology and Obstetrics and the
Institutional Review Board (IRB) at the Johns
Hopkins University (JHU) School of
Medicine, and a Health Insurance Portability
and Accountability (HIPAA) waiver. The
requirement for informed consent was waived
by the IRB because drawing blood from the
placenta involves no more than minimal risk
to the subjects, and the biosamples collected
would otherwise have been discarded. Strict
safeguards preserving patient confidentiality
were established. Members of a community
advisory committee, who were selected for
their specific knowledge and expertise on
important child health concerns in Maryland,
had the opportunity to learn about and com-
ment on this study. 
Data collection. Nurses or physicians who
routinely collect cord blood specimens for
clinical purposes obtained umbilical vein
blood using a syringe immediately after new-
born delivery but before the delivery of the
placenta (Witter et al. 2001). The cord blood
was transferred from the syringes to silicon-
coated (PBDE-free) vacutainers that were
stored for a maximum of 3 hr at 4°C. The
vacutainers were centrifuged at 2,400 × g for
15 min, and serum was pipetted into pre-
screened amber glass vials with Teflon-lined
screw caps, which were immediately stored at
–80°C (Sjodin et al. 2004b). Frozen speci-
mens were transferred on dry ice to the
Centers for Disease Control and Prevention
(CDC) for laboratory analyses. 
Details regarding the analysis of the serum
samples for PBDEs and PCBs are described
elsewhere (Sjodin et al. 2004b). Briefly, the
samples were fortiﬁed with 13C-labeled inter-
nal standards and formic acid and water for
denaturation and dilution using a Gilson 215
liquid automated handler (Gilson Inc.,
Middleton, WI). The samples were extracted
using the Rapid Trace (Caliper Life Sciences,
Hopkinton, MA) modular solid phase extrac-
tion (SPE) system. Lipids were co-extracted
using the SPE system and were removed on a
silica:silica/sulfuric acid column. The ﬁnal ana-
lytic determinations were performed using a
gas chromatography isotope dilution high reso-
lution mass spectrometry employing a
MAT95XP (ThermoFinnigan MAT, Bremen,
Germany) instrument. The serum lipid con-
centration was determined by use of commer-
cially available test kits from Roche Diagnostics
Corp. (Indianapolis, IN) for the quantitative
determination of total triglycerides (product
no. 011002803-0600) and total cholesterol
(product no. 011573303-0600). Final deter-
minations were made on a Hitachi 912 chem-
istry analyzer (Hitachi, Tokyo, Japan).
A total of 297 of the 300 cord serum sam-
ples were successfully analyzed. The limits of
detection (LOD) were defined both in rela-
tion to the method blanks and the instrumen-
tal detection limit (Sjodin et al. 2004b). We
analyzed the serum samples for the following
PBDE congeners (International Union of
Pure and Applied Chemistry numbers):
2,4,4´-tribromodiphenyl ether (BDE-28),
2,2´,4,4´-tetraBDE (BDE-47), 2,2´,3,4,4´-
pentaBDE (BDE-85), 2,2´,4,4´,5-pentaBDE
(BDE-99), 2,2´,4,4´,6-pentaBDE (BDE-
100), 2,2´,4,4´,5,5´-hexaBDE (BDE-153),
2,2´,4,4´,5,6´-hexaBDE (BDE-154), and
2,2´,3,4,4´,5´,6-heptaBDE (BDE-183). We
analyzed 21 samples for decaBDE (BDE-209);
all of these specimens had a concentration
below the LOD. Because of this observation,
the concentration of BDE-209 was not deter-
mined in remaining specimens. The median
LOD for BDE-209 was 3.0 ng/g lipid, and
the range was 2.0–3.7. The samples were also
analyzed for 35 PCB congeners [the full list is
available in Supplemental Material, Table 1
(online at http://www.ehponline.org/mem-
bers/2007/10333/suppl.pdf)]; the results of
the following four congeners are presented
here: 2,3´,4,4´,5-pentaCB (CB-118),
2,2´,3,4,4´,5´-hexaCB/2,3,3´,4,4´,6-hexaCB
(CB-138/158, co-elution), 2,2´,4,4´,5,5´-
hexaCB (CB-153), and 2,2´,3,4,4´,5,5´-
heptaCB (CB-180). The specimens were also
analyzed for 9 persistent pesticides, of which
only 2,2-bis(4-chlorophenyl)-1,1-dichloro-
ethene (p,p´-DDE), the primary degradation
product of p,p´-DDT (dichlorodiphenyl-
trichloroethane), is reported here. We meas-
ured cotinine concentrations in cord blood by
use of liquid chromatography in conjunction
with atmospheric pressure ionization tandem
mass spectrometry (Bernert et al. 1997). 
Demographic information and biological
measures were abstracted from the maternal
medical records by two study personnel, and a
10% random sample was re-reviewed by study
clinicians. Additional information was
obtained from forms completed by the nursing
staff at the time of delivery. Age, education,
marital status, and parity were self-reported.
Self-reported maternal race was also recorded
because it appeared in the medical records as
one of three categories: African American,
Caucasian, and Asian. No further information
was available regarding length of residency in
the United States or a further ethnic break-
down within these three race categories.
Smoking status was deﬁned using a combina-
tion of the maternal medical record and cord
serum cotinine concentrations; levels > 10
ng/mL were categorized as maternal active
smoking (CDC 2005). If the clinical record
indicated that the mother reported smoking at
any time during pregnancy, she was considered
an active smoker, regardless of the cotinine
concentration. Maternal street addresses were
geocoded by GeoLytics Inc. (East Brunswick,
NJ), who also provided census information at
the block-group level. Once data collection was
completed, medical record numbers and
addresses were deleted from study databases
and files. Geographic locations were main-
tained at the block-group level. 
Data analyses. PCB and PBDE distribu-
tions were log-normally distributed; medians
and interquartile ranges (IQRs) are presented,
and concentrations were log-transformed for
regression analyses. To conﬁrm that the distri-
butions conformed to the assumptions of nor-
mality, (P-P) plots (graphical representations
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compared with a normal distribution) were
used. For analytes below the LOD, the value
imputed is the LOD divided by the square
root of 2. PCB and PBDE concentrations
were expressed as nanograms per gram lipid. 
We used Spearman correlation coeffi-
cients to explore bivariate relationships
between various PBDEs and organohalogen
compounds. PCBs 118, 138/158 (co-eluting
congeners), 153, and 180 were selected for
further analysis on the basis of their propor-
tional contribution to the ΣPCB concentra-
tion and having a large proportion of the
samples with detectable levels. Only PBDEs
with ≥ 60% detectable (BDE-47, BDE-100,
and BDE-153) were evaluated further. We
developed univariate and multivariate linear
regression models for these congeners. To
avoid excluding observations in multivariate
analyses, we substituted the median for miss-
ing values [4 median substitutions for mater-
nal education, 7 for timing of first prenatal
visit, 9 for weight gain during pregnancy, 4
for median household income, and 11 for
body mass index (BMI)]. Also, “high” expo-
sure groups were deﬁned as individuals in the
highest 10% of the exposure distribution for
BDE-47, BDE-153, CB-153, and CB-180
concentrations, respectively; this end point
was modeled using multivariate logistic
regression models. We evaluated statistical
differences by exposure group by Student’s
t-test and Fisher’s exact test. All statistical
analyses were conducted using STATA, ver-
sion 8.0 (StataCorp., College Station, TX). 
Results
Of the 300 samples sent for PCB and PBDE
analyses, 297 successfully underwent sample
preparation and quantification. The 41
infants with insufﬁcient serum quantity were
more likely to be the first born (61% vs.
42%), preterm (24% vs. 13%), and/or low
birth weight (22% vs. 11%). Concentrations
(nanograms per gram lipid) of analyzed
PBDE and selected PCB congeners are given
in Table 1, with the percentage of results
above the LOD. Ninety-four percent of the
cord samples contained at least one detectable
BDE congener, and > 99% had at least one
detectable PCB congener. Among the eight
BDE congeners monitored, the tetrabromi-
nated BDE-47 was the dominant congener by
weight, accounting, on average, for 51.2% of
the ΣPBDE concentration. In order of
decreasing abundance, BDE-47 was followed
by BDE-99 (12.0%), BDE-153 (8.2%), and
BDE-100 (8.1%), with BDE-28, BDE-85,
BDE-154, and BDE-183 each accounting for
< 4% of the ΣPBDE concentration. We cal-
culated Spearman correlations between pairs
of selected PCB and PBDE congeners and
DDE. In general, the correlations were the
highest within each compound class, whereas
PCB and PBDE congeners were not highly
correlated with each other. PCBs but not
PBDEs were correlated with serum DDE lev-
els [see Supplemental Material, Table 2
(online at http://www.ehponline.org/
members/2007/10333/suppl.pdf)].
In this population, the mean (± SD)
maternal age was 25.9 ± 6.6 years. Most (70%)
were African American, with 21% Caucasian
and 8% Asian. Most (66%) of the mothers
were unmarried, and a large proportion (29%)
had less than a high school education. Use of
standardized categories of BMI showed that
almost half of the mothers were overweight or
obese before pregnancy (National Institutes of
Health 1998). On the basis of self-reported
smoking status, 15% of women smoked
tobacco during the pregnancy. However, after
validating self-reported tobacco use with cord
serum cotinine levels, 19% were classified as
active smokers during pregnancy. Nearly 70%
resided within the Baltimore city limits. 
Median and interquartile ranges of lipid-
adjusted PBDE and PCB concentrations are
shown in Figures 1 and 2, stratiﬁed by demo-
graphic variables. These univariate analyses
show general exposure patterns for the two sets
of compounds. The relationships between the
covariates presented in Figures 1 and 2 and
cord serum concentrations were evaluated by
use of multivariate linear regression models
(Tables 2 and 3). The adjusted regression coef-
ﬁcients were compared with unadjusted regres-
sion coefﬁcients to evaluate confounding. 
In a multivariate model of cord BDE-47,
younger maternal age, less pregnancy weight
gain, having ≥ 5 years of college education,
Herbstman et al.
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Table 1. Lipid-adjusted concentrations and congener distributions of PBDEs and selective PCBs (and DDE
for comparison) in umbilical cord blood serum (n = 297). 
Congener
Percent Median LOD Median Range distributiona
Congener > LOD (ng/g serum lipid) (ng/g serum lipid) (ng/g serum lipid) (median %)
BDE-28 29.6 1.1 0.9 ND–9.8 3.0
BDE-47 90.2 1.3 13.6 ND–311.2 51.2
BDE-85 15.8 1.3 1.1 ND–12.9 3.9
BDE-99 46.5 2.1 4.3 ND–83.4 12.0
BDE-100 64.5 1.2 2.3 ND–77.0 8.1
BDE-153 60.3 1.3 2.6 ND–154.3 8.2
BDE-154 6.1 1.1 0.9 ND–10.1 3.0
BDE-183 7.1 1.1 0.9 ND–13.2 3.3
CB-118b 95.6 1.1 3.0 ND–97.5 6.3
CB-138/158 98.0 1.1 4.9 ND–60.2 10.9
CB-153 99.7 1.1 6.4 ND–72.4 13.9
CB-180 89.6 1.1 2.6 ND–68.8 5.8
DDE 100.0 1.1 53.5 3.9–7,710 NA
ND, not detected.
aPBDE congener distribution based on the proportional contribution of 8 congeners; PCB congener distribution based on
the proportional contribution of 35 congeners. bDioxin-like PCB.
Figure 1. Univariate (unadjusted) relationships between lipid-adjusted PBDE levels in cord blood serum
and sample characteristics. The median and QR are represented by error bars; the vertical line is the over-
all median for this population. Black and white symbols distinguish between variables.
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(ng/g lipid)and being classified as obese prepregnancy
were independently associated with increased
cord blood levels (Table 2). For BDE-100,
only maternal smoking during pregnancy was
predictive of higher cord blood levels in a mul-
tivariate model. For BDE-153, the multivari-
ate model indicated that younger maternal
age, less weight gain during pregnancy, and
smoking during pregnancy were associated
with higher cord blood levels. Asian infants
had lower mean cord levels of BDE-47 and
BDE-153. The multivariate models indicate
that the univariate relationships between
some of the independent variables and PBDE
exposure were confounded. For example, for
BDE-47, a number of variables—maternal
race, median household income in the neigh-
borhood, marital status, and residence in or
outside of the Baltimore city limits—were no
longer associated with cord serum levels after
controlling for maternal age, weight gain
during pregnancy, education, and BMI. 
In the case of PCB serum levels (Table 3),
both univariate and multivariate linear
regression models for CB-118, CB-138/158,
CB-153, and CB-180 indicated that maternal
age was positively associated with umbilical
cord PCB levels. For CB-118, in addition to
maternal age, the multivariate model indicated
that infants of unmarried mothers and mothers
having ≥ 5 years of college education had
increased exposure. In the case of CB-138/158,
infants of older mothers, unmarried mothers,
and mothers who smoked during pregnancy
had higher mean exposure levels. Infants of
Asian and obese mothers had lower mean cord
levels of CB-138/158. For both CB-153 and
CB-180, the multivariate models indicated
that besides increasing maternal age, lower
birth order (parity), being unmarried, and
maternal smoking during pregnancy were
independently associated with higher cord lev-
els. Infants of Asian and obese mothers had
lower mean cord serum level of CB-153 and
CB-180. Similar to PBDEs, the PCB multi-
variate models suggest that some of the uni-
variate relationships were confounded. 
Within our population, subgroups of high
exposure were identified as described above.
Ten individuals were in the highest decile of
both BDE-47 and BDE-153, and 23 individu-
als were in the highest of both CB-153 and
CB-180. Only one individual was in the high-
est decile of all four congeners considered in
this analysis. The odds of being in the highest
decile of exposure were examined for these four
congeners using multivariate logistic regression
and the same independent variables as pre-
sented in Tables 2 and 3. Although the 95%
conﬁdence intervals (CIs) are wide, infants of
mothers who smoked during pregnancy [odds
ratio (OR) = 4.10; 95% CI, 1.51–11.10] and
those whose mothers had completed ≥ 5 years
of post–high school education (OR = 11.51;
95% CI, 1.36–97.66) were signiﬁcantly more
likely to be in the high BDE-47 exposure
group. There were no covariates signiﬁcantly
associated with being in the high BDE-153
exposure group. Infants of older mothers (OR
= 1.42, 95% CI, 1.26–1.61; OR = 1.44, 95%
CI, 1.26–1.64) and mothers with a prior child-
birth (OR = 6.06, 95% CI, 1.57–23.45; OR =
6.76, 95% CI, 1.68–27.16) were more likely to
be in the high CB-153 and CB-180 exposure
groupings, respectively. 
Discussion
We measured PBDE and PCB concentrations
in cord serum of 297 neonates born at an
inner-city referral hospital. To date there are
few data with regard to exposures in inner-
city, largely African-American populations.
Although concentrations of individual
PBDEs and PCB congeners were correlated
within classes, they were not well correlated
across classes. Some studies have reported
positive correlations between these two classes
of compounds in humans (Kalantzi et al.
2004) and in ﬁsh (Hale et al. 2001; Hayward
et al. 2004). Others, including ours, report no
such association (Bradman et al. 2007;
Johnson-Restrepo et al. 2005; Thomas et al.
2005). Although PBDEs are found in a vari-
ety of household and consumer products,
PCBs no longer are manufactured for use,
and most existing uses have been phased out.
This is consistent with the ﬁnding that PCBs,
but not PBDEs, are correlated with p,p´-DDE
levels. p,p´-DDE is the degradation product
of p,p´-DDT, which has not been actively
used in the United States for decades.
Differences in PCB and PBDE toxicokinetics
may also play a role (Johnson-Restrepo et al.
2005). Generally, as well as in our study, the
distribution of PBDEs in humans is log-nor-
mally distributed such that approximately 5%
of the sample has PBDE levels that are 3–5
times higher than the median (Jones-Otazo
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Figure 2. Univariate (unadjusted) relationships between lipid-adjusted PCB levels in cord blood serum and sample characteristics. The median and IQR are repre-
sented by error bars; the vertical line is the overall median for this population. Black and white symbols distinguish between variables.
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(ng/g lipid)et al. 2005; She et al. 2004; Wilford et al.
2005; Wu et al. 2007). Of these, very few
were also highly exposed to PCBs, an observa-
tion that may indicate that differing routes of
exposure or temporal differences in patterns
of use are responsible for the highest levels. 
To date, two other published studies have
reported PBDE levels in cord blood: one in
Sweden and one in Indiana (USA) (Mazdai
et al. 2003), both in 2001. Although these
studies are much smaller than ours, the
Indiana study reported similar concentrations
of PBDEs in cord blood (median ΣPBDE,
39 ng/g serum lipid; range, 14–460 ng/g)
(Mazdai et al. 2003). Our concentrations
were more than an order of magnitude higher
than the Swedish levels (median ΣPBDE,
1.7 ng/g serum lipid; range, 0.5–4.3 ng/g)
(Guvenius et al. 2003). An additional study
that evaluated the concentration of PBDEs in
human fetal livers (n = 11) reported lower
concentrations (median ΣPBDE, 15.2 ng/g
lipid; range, 4.0–98.5 ng/g) than those meas-
ured in this study (Schecter et al. 2007).
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Table 3. β coefﬁcients, indicating change in (ln)PCB concentrations, from univariate and multivariatea regression models for selected PCBs. 
CB-118 CB-138/158 CB-153 CB-180
β Adjusted β (95% CI) β Adjusted β (95% CI) β Adjusted β (95% CI) β Adjusted β (95% CI)
Maternal age (per 5 years) 0.17** 0.22** (0.15 to 0.30) 0.31** 0.39** (0.31 to 0.46) 0.36** 0.44** (0.37 to 0.51) 0.48** 0.55** (0.40 to 0.62)
Maternal weight gainb (per 10 lb) –0.01 –0.01 (–0.05 to 0.03) 0.01 –0.01 (–0.05 to 0.03) 0.01 –0.02 (–0.06 to 0.02) 0.02 –0.02 (–0.06 to 0.02)
Median household incomec (per $10,000) 0.04 0.01 (–0.04 to 0.06) 0.06** 0.00 (–0.05 to 0.05) 0.08** 0.01 (–0.03 to 0.05) 0.13** 0.02 (–0.02 to 0.07)
Parity (reference nulliparous, n = 123)
Multiparous (n = 174) 0.02 –0.15 (–0.32 to 0.03) 0.18* –0.13 (–0.30 to 0.03) 0.18* –0.17* (–0.32 to –0.02) 0.26* –0.16* (–0.32 to 0.00)
Race (reference Caucasian, n = 64)
Asian (n = 23) 0.03 –0.11 (–0.43 to 0.21) –0.11 –0.33* (–0.64 to –0.02) –0.04 –0.31* (–0.59 to –0.02) –0.19 –0.52**(–0.81 to –0.22)
African American (n = 210) –0.11 0.03 (–0.22 to 0.28) –0.26* 0.10 (–0.14 to 0.34) –0.33** 0.15 (–0.07 to 0.37) –0.57** 0.09 (–0.13 to 0.31)
Marital status (reference unmarried, n = 198)
Married (n = 99) 0.12 –0.34**(–0.60 to –0.08) 0.28** –0.34**(–0.58 to –0.09) 0.40** –0.28* (–0.51 to –0.05) 0.61** –0.26 (–0.50 to –0.03)
Maternal educationd(reference < high school, n = 86)
High school graduate (n = 101) 0.03 0.05 (–0.14 to 0.24) –0.02 –0.02 (–0.21 to 0.16) 0.01 –0.03 (–0.20 to 0.14) 0.00 –0.07 (–0.24 to 0.10)
1–4 years college (n = 70) 0.09 0.15 (–0.10 to 0.41) 0.16 0.09 (–0.15 to 0.33) 0.19 0.01 (–0.22 to 0.23) 0.31* –0.02 (–0.25 to 0.21)
≥ 5 years college (n = 40) 0.42** 0.41 (0.04 to 0.78) 0.54** 0.32 (–0.03 to 0.67) 0.70** 0.24 (–0.09 to 0.57) 0.92** 0.22 (–0.11 to 0.56)
Prenatal caree(reference 1st or 2nd trimester, n = 281)
None or 3rd trimester (n = 16) 0.04 –0.02 (–0.36 to 0.33) –0.02 –0.10 (–0.43 to 0.23) 0.04 –0.05 (–0.35 to 0.26) 0.10 0.03 (–0.28 to 0.34)
Smoking during pregnancy (reference nonsmoker, n = 242)
Smoker (n = 55) 0.09 0.10 (–0.10 to 0.30) 0.34** 0.30** (0.11 to 0.49) 0.27* 0.21* (0.04 to 0.39) 0.30* 0.24** (0.06 to 0.42)
BMIf (kg/m2) (reference normal, n = 135)
Underweight (n = 11) –0.25 –0.24 (–0.58 to 0.10) –0.23 –0.23 (–0.56 to 0.09) –0.27 –0.25 (–0.56 to 0.05) –0.22 –0.19 (–0.49 to 0.12)
Overweight (n = 65) –0.13 –0.07 (–0.43 to 0.29) –0.29 –0.25 (–0.59 to 0.09) –0.41 –0.35* (–0.67 to –0.03) –0.50* –0.39* (–0.72 to –0.07)
Obese (n = 71) –0.24 –0.20 (–0.57 to 0.16) –0.49* –0.48**(–0.83 to –0.14) –0.64** –0.62**(–0.94 to –0.30) –0.74** –0.67**(–1.00 to –0.34)
Resides in city (reference outside city limits, n = 92)
Within city limits (n = 205) –0.04 0.12 (–0.10 to 0.34) –0.17 0.06 (–0.15 to 0.27) –0.22* 0.09 (–0.10 to 0.29) –0.39** 0.09 (–0.11 to 0.28)
n= 297 unless otherwise noted.
aMultivariate models adjusted for all covariates.bNine missing; coded as median (30 lbs). cFour missing; coded as median ($31,860). dFour missing; coded as median (HS graduate).
eSix missing; coded as median (2nd trimester). fEleven missing; coded with an indicator variable. *p < 0.05. **p < 0.01.
Table 2. β coefﬁcients, indicating change in (ln)PBDE concentrations, from univariate and multivariatea regression models for selected PBDEs. 
BDE-47 BDE-100 BDE-153
β Adjusted β (95% CI) β Adjusted β (95% CI) β Adjusted β (95% CI)
Maternal age (per 5 years) –0.76** –0.14* (–0.25 to –0.02) –0.10** –0.10 (–0.21 to 0.00) –0.13** –0.15** (–0.26 to –0.04)
Maternal weight gainb (per 10 lb) –1.09** –0.08* (–0.14 to –0.01) –0.06* –0.04 (–0.10 to 0.02) –0.07* –0.07* (–0.13 to 0.00)
Median household incomec(per $10,000) –0.10** –0.03 (–0.10 to 0.04) –0.07** –0.01 (–0.08 to 0.06) –0.02 0.04 (–0.03 to 0.11)
Parity (reference nulliparous, n = 123)
Multiparous (n = 174) 0.20 0.19 (–0.06 to 0.44) 0.22* 0.20 (–0.04 to 0.44) 0.06 0.13 (–0.12 to 0.38)
Race (reference Caucasian, n = 64)
Asian (n = 23) –0.56** –0.70** (–1.17 to –0.23) –0.34 –0.40 (–0.85 to 0.05) –0.53* –0.59* (–1.06 to –0.12)
African American (n = 210) 0.40** 0.04 (–0.32 to 0.40) 0.36** 0.08 (–0.27 to 0.42) 0.13 –0.06 (–0.42 to 0.29)
Marital status (reference unmarried, n = 198)
Married (n = 99) –0.51** 0.00 (–0.38 to 0.38) –0.34** 0.14 (–0.22 to 0.50) –0.26* 0.10 (–0.27 to 0.48)
Maternal educationd(reference < high school, n = 86)
High school graduate (n = 101) –0.16 0.04 (–0.24 to 0.32) –0.01 0.16 (–0.11 to 0.42) –0.01 0.18 (–0.09 to 0.46)
1–4 years college (n = 70) –0.49** 0.06 (–0.31 to 0.43) –0.34* 0.08 (–0.26 to 0.43) –0.30* 0.09 (–0.27 to 0.46)
≥ 5 years college (n = 40) –0.54** 0.57* ( 0.04 to 1.11) –0.41* 0.37 (–0.14 to 0.88) –0.28 0.33 (–0.21 to 0.86)
Prenatal caree(reference 1st or 2nd trimester, n = 281)
None or 3rd trimester (n = 16) 0.36 0.23 (–0.27 to 0.73) 0.11 0.02 (–0.46 to 0.49) 0.07 0.05 (–0.44 to 0.55)
Smoking during pregnancy (reference nonsmoker, n = 242)
Smoker (n = 55) 0.30* 0.22 (–0.07 to 0.51) 0.42** 0.40** ( 0.12 to 0.68) 0.42** 0.42** ( 0.13 to 0.71)
BMIf (kg/m2) (reference normal, n = 135)
Underweight (n = 11) 0.43 0.55* ( 0.06 to 1.04) 0.05 0.16 (–0.31 to 0.63) –0.01 0.16 (–0.33 to 0.65)
Overweight (n = 65) 0.68* 0.70** ( 0.18 to 1.22) 0.31 0.34 (–0.16 to 0.84) 0.04 0.11 (–0.41 to 0.63)
Obese (n = 71) 1.02** 0.93** ( 0.40 to 1.46) 0.44 0.42 (–0.09 to 0.92) –0.09 –0.06 (–0.59 to 0.46)
Resides in city (reference outside city limits, n = 92)
Within city limits (n = 205) 0.47** 0.14 (–0.18 to 0.45) 0.43** 0.24 (–0.06 to 0.54) 0.34** 0.30 (–0.02 to 0.61)
n = 297 unless otherwise noted.
aMultivariate models adjusted for all covariates. bNine missing; coded as median (30 lb). cFour missing; coded as median ($31,860). dFour missing; coded as median (high school gradu-
ate). eSix missing; coded as median (2nd trimester). fEleven missing; coded with an indicator variable. *p < 0.05. **p < 0.01.Levels of PBDEs in cord blood are roughly
equivalent to those found in maternal blood
on a lipid-adjusted basis (Mazdai et al. 2003),
and PBDEs measured on a per-lipid basis
may be compared across matrices. PBDE lev-
els in human milk in two U.S. studies are
similar to what was measured in our study
population on a lipid weight basis (Schecter et
al. 2003; Wu et al. 2007). From these com-
parisons, albeit limited because of different
sets of congeners contributing to the total
exposure (Σ measurement) in each study, we
conclude that the levels found in this study
are consistent with U.S. levels reported else-
where and are much higher than levels in
Sweden (Bradman et al. 2007; Hites 2004;
Wu et al. 2007). 
In most human samples, BDE-47 has
been identified as the dominant congener in
terms of concentration (Hites 2004; Schecter
et al. 2007; Sjodin et al. 2001b). However,
there are some populations (mainly in Europe)
and a small proportion of individuals within
U.S. populations in which BDE-153 is instead
the dominant PBDE congener in humans
(Covaci et al. 2002; Naert et al. 2006; She
et al. 2004; Thomas et al. 2005; Wu et al.
2007). This second pattern is present among
5% of our population. This difference may
reflect variable exposure pathways or toxico-
kinetics or, alternatively, differences in diet
among individuals from countries or ethnic
groups where BDE-47 is not the dominant
congener in foods (Covaci et al. 2002).
Several factors independently predicted
exposures to PCBs and PBDEs in multivariate
models. The direction of some of these associ-
ations was surprisingly different between these
two compound classes. PBDEs tended to
decrease with older maternal age, whereas
PCBs consistently increased. Women who were
obese before pregnancy had higher BDE-47
levels. However, for CB-138/158, CB-153,
and CB-180, prepregnancy obesity was associ-
ated with lower exposure levels. Asians gener-
ally had lower PCB and PBDE levels than
Caucasians. In addition to differences in expo-
sure routes and pathways, immigration pat-
terns (including the number of years since
immigrating to the United States) may partly
explain these differences. However, these data
were not available for analysis in this study.
The observed positive association between
maternal age with PCB levels was expected. In
contrast, maternal age was independently nega-
tively associated with each and all PBDE con-
geners. The levels of PBDEs are still increasing
or have been increasing until recently in the
general U.S. population, making the inﬂuence
of accumulation with age less important
(Sjodin et al. 2004a). In this way, if most of
the exposure to high levels of PBDEs has
occurred more recently in time, a person’s
length of time with high exposure may be
independent of age. Another possible explana-
tion is that PBDEs have shorter half-lives com-
pared with PCBs (Ogura 2004). Other studies
have not observed a relationship between age
and PBDE concentrations, independent of
parity (Schecter et al. 2003; Sjodin et al. 1999,
2003). However, the study by Schecter et al.
(2005), which included men and a broader age
range, reported a “suggested” inverse associa-
tion between PBDE levels and age. Among our
population, the inverse association with mater-
nal age and PBDEs corresponds to a 12-ng/g
lipid decrease in predicted average BDE-47
concentrations over the entire age range in the
study (14–43 years). Although the maternal
age range in this study covers only one genera-
tion, there is the possibility of a behavioral
cohort effect, such that younger women may
have more contact with consumer products
containing PBDEs or have higher consump-
tion of PBDE-containing foods. An associa-
tion with diet is also suggested by the higher
levels among women with obese prepregnancy
BMI, although this may reﬂect lifestyle differ-
ences as well. 
As expected, multivariate models indicate
that body burden of PCBs (CB-153 and
CB-180) decreased with increased maternal
parity. That is consistent with the notion that
pregnancy is one of the major routes of elimi-
nation for PCBs as well as other lipophilic
POPs (Barr et al. 2005). However, we found
no evidence for a decrease in PBDE levels
with increased numbers of pregnancy in our
study. Lactation is another mechanism for the
excretion of PCBs and PBDEs. In this study,
information about previous lactation history
was unavailable. 
Dilution of organohalogen levels via
weight gain is another mechanism that could
explain lower levels in subjects with a higher
BMI. In our population, consistent with
other studies, women with very high (obese)
prepregnancy BMIs consistently had lower
lipid-adjusted PCB levels, and very under-
weight women tended to have higher PCB
levels than did women with normal prepreg-
nancy weight (Glynn et al. 2007). However,
such a “fat dilution” phenomenon was not
observed for PBDEs; if anything, obese
women had higher exposure levels (in the case
of BDE-47 and BDE-100). Conversely,
reduced weight gain during pregnancy tended
to be associated with higher levels of exposure
to PBDEs. A study examining the effect of
the commercially available DE-71 mixture
(consisting of primarily tetra and penta
PBDE congeners) in rats did not ﬁnd an asso-
ciation between weight gain during pregnancy
and exposure (Zhou et al. 2002). In this
cross-sectional study, it is not possible to
determine whether reduced weight gain dur-
ing pregnancy is a predictor or the conse-
quence of high concentrations of PBDEs. 
Smoking during pregnancy was associated
with higher cord blood levels of both PCBs
and PBDEs. Smokers have increased hand-to-
mouth behavior that can increase oral inges-
tion of contaminated dust in the environment
among smokers or altered mucociliary clear-
ance processes in the upper airways of smokers,
potentially leading to ingestion of mucus-con-
taining inhaled PBDE particles (Phillips et al.
2003). However, particle ingestion would not
explain why smokers also have elevated levels
of PCBs, which are not typically found in dust.
Smoking may also be associated with other
lifestyle factors (including diet) which we were
not able to evaluate in this study. Alternatively,
smoking alters PCB and PBDE exposure levels
via alteration in either maternal or fetal hepatic
enzymes (or both). Certainly, smoking induces
cytochrome P450 1A2, which has been shown
to be involved in metabolism of mono-ortho
PCBs (Ayotte et al. 2005), such as CB-118,
which is the one PCB that was not associated
with smoking in our study. This, however,
would not explain why levels of the di-ortho
PCBs such as CB-153 and CB-180 as well as
PBDE levels were higher among smokers.
Though not readily explained, these associa-
tions were consistent and need further study.
In this study, we examined individual and
spatial determinants of PBDE exposure that
might explain the wide distribution of blood
levels evident in this population. Although
many of these factors were signiﬁcant predictors
of exposure, overall, most of the variation was
unexplained, implying that other unmeasured
factors account for this variation. These factors
may be related to differential exposure (i.e.,
dietary differences or differences in micro-
environments), which we were unable to collect
in this population. It is also possible that the
wide variation detected in cord blood serum
levels might be related to interindividual genetic
differences that impact the ability to absorb,
metabolize, or excrete these compounds. 
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